Syros Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company's customers operate under various federal and state health care laws and regulations, including the federal Anti-Kickback Statute, false claims laws, the Foreign Corrupt Practices Act, and the federal Physician Payments Sunshine Act. These laws govern interactions with federal health care programs such as Medicare and Medicaid and mandate transparency in payments to physicians and teaching hospitals. The market comprises pharmaceutical companies required to comply with these regulations, as well as third-party payors including government health programs (Medicare and Medicaid), commercial health insurers, and managed care organizations that reimburse patients and providers for treatments and services. Coverage and reimbursement decisions by these third-party payors have a significant impact on product sales.
Syros Pharmaceuticals Announces Strategic Business Restructuring and Clinical Trial Developments Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), based in Cambridge, Massachusetts, continues to pioneer advancements in the field of hematologic malignancies. Today, the company has made significant announcements regarding its future trajectory and ongoing clinical research endeavors, highlighting its strategy to streamline operations while advancing medical research.Following a strategic decision, Syros Pharmaceuticals has revealed its intention to voluntarily delist its common stock from the Nasdaq Stock Market. Additionally, it will deregister its common stock to suspend reporting obligations under the Securities a...
Syros Pharmaceuticals Reports Second Quarter 2024 Financial Results: A Summary of Revenue Decline and Business UpdatesSyros Pharmaceuticals, a leading biopharmaceutical company specializing in the treatment of hematologic malignancies, has announced that it will be hosting a live conference call and webcast on July 31, 2024. The purpose of this event is to report the company s financial results for the second quarter of 2024 and provide an update on its business operations.During the specified time frame, Syros Pharmaceuticals Inc experienced a significant decline in revenue. Year on year, the company s revenue deteriorated by an alarming 54.86%. Additionally, sequentially, revenue fell by 4.1%. This decline...
In a significant development for the biopharmaceutical industry, Syros Pharmaceuticals has announced the successful completion of patient enrollment in the SELECT-MDS-1 Phase 3 clinical trial. The trial aims to evaluate the efficacy of tamibarotene in treating newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression. With the enrollment of 190 patients, this crucial initial cohort constitutes the necessary support for the primary endpoint analysis.Myelodysplastic syndromes (MDS) are a group of hematological malignancies characterized by ineffective production of blood cells, leading to a wide range of symptoms and medical complications. HR-MDS, in particular, poses...
Syros Pharmaceuticals, a prominent biopharmaceutical company headquartered in Cambridge, Massachusetts, has recently released its anticipated milestones for the year 2024. As a leader in the development of innovative treatments for hematologic malignancies, Syros Pharmaceuticals is seizing the new year with zeal and renewed commitment towards the advancement of its promising therapeutic solution, Tamibarotene.Despite experiencing a significant 54.86% year-on-year revenue decline, and a sequential revenue fall of 4.1%, the company remains steadfast in its mission. Bucking the waves of financial setbacks, Syros has set afoot on a path that could potentially revolutionize the standard of care for patients suffe...
Syros Pharmaceuticals, a leading biopharmaceutical company focused on revolutionizing treatment options for hematologic malignancies, has recently released encouraging initial data from its ongoing SELECT-AML-1 Phase 2 clinical trial. The trial evaluates the efficacy of tamibarotene, an oral medication that acts as a selective retinoic acid receptor alpha (RAR) agonist, in combination with venetoclax and azacitidine for newly diagnosed, unfit patients with acute myeloid leukemia (AML). The initial results from the trial have shown strong potential, serving as a ray of hope for patients suffering from this aggressive and life-threatening form of cancer. AML is a type of blood and bone marrow cancer ...
Syros Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company's customers operate under various federal and state health care laws and regulations, including the federal Anti-Kickback Statute, false claims laws, the Foreign Corrupt Practices Act, and the federal Physician Payments Sunshine Act. These laws govern interactions with federal health care programs such as Medicare and Medicaid and mandate transparency in payments to physicians and teaching hospitals. The market comprises pharmaceutical companies required to comply with these regulations, as well as third-party payors including government health programs (Medicare and Medicaid), commercial health insurers, and managed care organizations that reimburse patients and providers for treatments and services. Coverage and reimbursement decisions by these third-party payors have a significant impact on product sales.
Sources:
Syros Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Syros Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Syros Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
